Key result
Comorbid hypertension, diabetes, and obesity are linked to ~3.5-fold higher cardiotrophin-1 levels versus controls.
Why the study?
Timely identification of factors contributing to early development of cardiovascular complications in patients with comorbid conditions such as hypertension, type 2 diabetes, and obesity is important.
Cross-Sectional (n=211)
No
Cardiotrophin-1 is significantly elevated in patients with arterial hypertension and metabolic comorbidities, suggesting it may serve as an independent biomarker for the early detection of atherosclerotic changes and elevated cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Cardiotrophin-1 elevation may mark early atherosclerosis risk in comorbid patients; hypothesis-generating and should not yet change practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Бiловол et al. (2025) conducted a cross-sectional in Arterial hypertension, type 2 diabetes mellitus, and obesity (n=211). Comorbid pathology (arterial hypertension, type 2 diabetes mellitus, obesity) vs. Healthy individuals was evaluated on Cardiotrophin-1 (CTF-1) level (p=≤0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: